Treatment Approaches for FGFR-altered Urothelial Carcinoma: Targeted Therapies and Immunotherapy

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2023 Sep 7

PMID 37675102

Authors

David J Benjamin

Robert Hsu

Affiliations

Soon will be listed here.

Abstract

The treatment of metastatic urothelial carcinoma has dramatically changed over the past decade with the approval of several therapies from multiple drug classes including immune checkpoint inhibitors, targeted therapies, and antibody drug conjugates. Although next generation sequencing of urothelial carcinoma has revealed multiple recurring mutations, only one targeted therapy has been developed and approved to date. Erdafitinib, a pan-fibroblast growth factor receptor (FGFR) inhibitor, has been approved for treating patients with select FGFR2 and FGFR3 alterations and fusions since 2019. Since then, emerging data has demonstrated efficacy of combining erdafitinib with immunotherapy in treating FGFR-altered urothelial carcinoma. Ongoing trials are evaluating the use of erdafitinib in non-muscle invasive urothelial carcinoma as well as in combination with enfortumab vedotin in the metastatic setting, while other FGFR targeted agents such as infigratinib, AZD4547, rogaratinib and pemigatinib continue to be in development. Future challenges will include strategies to overcome FGFR acquired resistance and efficacy and safety of combination therapies with erdafitinib and other FGFR targeted agents.

Citing Articles

Evolving Treatment Landscape of Frontline Therapy for Metastatic Urothelial Carcinoma: Current Insights and Future Perspectives.

Kwon W, Lee M Cancers (Basel). 2024; 16(23).

PMID: 39682263 PMC: 11640162. DOI: 10.3390/cancers16234078.

FGFR Inhibitors in Urothelial Cancer: From Scientific Rationale to Clinical Development.

Kwon W J Korean Med Sci. 2024; 39(43):e320.

PMID: 39536791 PMC: 11557252. DOI: 10.3346/jkms.2024.39.e320.

Platelets camouflaged nanovehicle improved bladder cancer immunotherapy by triggering pyroptosis.

Tian J, Gao M, Zhu J, Xu H, Ji H, Xia D Theranostics. 2024; 14(17):6692-6707.

PMID: 39479459 PMC: 11519802. DOI: 10.7150/thno.99040.

Emerging molecular therapies in the treatment of bladder cancer.

Bell S, Quinn A, Spitzer T, Voss B, Wakefield M, Fang Y Explor Target Antitumor Ther. 2024; 5(5):1135-1154.

PMID: 39351439 PMC: 11438598. DOI: 10.37349/etat.2024.00267.

New Advances in Metastatic Urothelial Cancer: A Narrative Review on Recent Developments and Future Perspectives.

Tonni E, Oltrecolli M, Pirola M, Tchawa C, Roccabruna S, DAgostino E Int J Mol Sci. 2024; 25(17).

PMID: 39273642 PMC: 11395814. DOI: 10.3390/ijms25179696.

References

Cowell J, Qin H, Hu T, Wu Q, Bhole A, Ren M . Mutation in the FGFR1 tyrosine kinase domain or inactivation of PTEN is associated with acquired resistance to FGFR inhibitors in FGFR1-driven leukemia/lymphomas. Int J Cancer. 2017; 141(9):1822-1829. PMC: 5850950. DOI: 10.1002/ijc.30848. View

ODonnell P, Milowsky M, Petrylak D, Hoimes C, Flaig T, Mar N . Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer. J Clin Oncol. 2023; 41(25):4107-4117. PMC: 10852367. DOI: 10.1200/JCO.22.02887. View

Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J . Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017; 18(3):312-322. DOI: 10.1016/S1470-2045(17)30065-7. View

Hernandez S, Lopez-Knowles E, Lloreta J, Kogevinas M, Amoros A, Tardon A . Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J Clin Oncol. 2006; 24(22):3664-71. DOI: 10.1200/JCO.2005.05.1771. View

Lyou Y, Grivas P, Rosenberg J, Hoffman-Censits J, Quinn D, Petrylak D . Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1-3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3-altered Advanced/Metastatic Urothelial Carcinoma. Eur Urol. 2020; 78(6):916-924. PMC: 8425313. DOI: 10.1016/j.eururo.2020.08.002. View

Subbiah V, Iannotti N, Gutierrez M, Smith D, Feliz L, Lihou C . FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies. Ann Oncol. 2022; 33(5):522-533. DOI: 10.1016/j.annonc.2022.02.001. View

Pal S, Bajorin D, Dizman N, Hoffman-Censits J, Quinn D, Petrylak D . Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell-free DNA results. Cancer. 2020; 126(11):2597-2606. PMC: 7515773. DOI: 10.1002/cncr.32806. View

van Rhijn B, Vis A, van der Kwast T, Kirkels W, Radvanyi F, Ooms E . Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol. 2003; 21(10):1912-21. DOI: 10.1200/JCO.2003.05.073. View

Knowles M, Hurst C . Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer. 2014; 15(1):25-41. DOI: 10.1038/nrc3817. View

10.

Jubber I, Ong S, Bukavina L, Black P, Comperat E, Kamat A . Epidemiology of Bladder Cancer in 2023: A Systematic Review of Risk Factors. Eur Urol. 2023; 84(2):176-190. DOI: 10.1016/j.eururo.2023.03.029. View

11.

Benjamin D, Mar N, Kalebasty A . Immunotherapy With Checkpoint Inhibitors in FGFR-Altered Urothelial Carcinoma. Clin Med Insights Oncol. 2022; 16:11795549221126252. PMC: 9520173. DOI: 10.1177/11795549221126252. View

12.

Jiang K, Tang X, Guo J, He R, Chan S, Song X . GZD824 overcomes FGFR1-V561F/M mutant resistance in vitro and in vivo. Cancer Med. 2021; 10(14):4874-4884. PMC: 8290231. DOI: 10.1002/cam4.4041. View

13.

Rosenberg J, Hoffman-Censits J, Powles T, van der Heijden M, Balar A, Necchi A . Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016; 387(10031):1909-20. PMC: 5480242. DOI: 10.1016/S0140-6736(16)00561-4. View

14.

Gomez-Roman J, Saenz P, Molina M, Gonzalez J, Escuredo K, Santa Cruz S . Fibroblast growth factor receptor 3 is overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth. Clin Cancer Res. 2005; 11(2 Pt 1):459-65. View

15.

Flaig T, Spiess P, Abern M, Agarwal N, Bangs R, Boorjian S . NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022. J Natl Compr Canc Netw. 2022; 20(8):866-878. DOI: 10.6004/jnccn.2022.0041. View

16.

Bahleda R, Italiano A, Hierro C, Mita A, Cervantes A, Chan N . Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors. Clin Cancer Res. 2019; 25(16):4888-4897. DOI: 10.1158/1078-0432.CCR-18-3334. View

17.

Perera T, Jovcheva E, Mevellec L, Vialard J, De Lange D, Verhulst T . Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor. Mol Cancer Ther. 2017; 16(6):1010-1020. DOI: 10.1158/1535-7163.MCT-16-0589. View

18.

Wang L, Sustic T, Leite de Oliveira R, Lieftink C, Halonen P, van de Ven M . A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma. Eur Urol. 2017; 71(6):858-862. DOI: 10.1016/j.eururo.2017.01.021. View

19.

Chalasani V, Chin J, Izawa J . Histologic variants of urothelial bladder cancer and nonurothelial histology in bladder cancer. Can Urol Assoc J. 2009; 3(6 Suppl 4):S193-8. PMC: 2792446. DOI: 10.5489/cuaj.1195. View

20.

DiBianco J, George A, Su D, Agarwal P . Managing noninvasive recurrences after definitive treatment for muscle-invasive bladder cancer or high-grade upper tract urothelial carcinoma. Curr Opin Urol. 2015; 25(5):468-75. DOI: 10.1097/MOU.0000000000000201. View